Ovid Therapeutics (OVID) Cash & Equivalents (2016 - 2026)

Ovid Therapeutics (OVID) has reported Cash & Equivalents for 11 consecutive years, with $11.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Equivalents fell 60.14% year-over-year to $11.3 million; the trailing twelve-month figure through Jun 2026 stood at $11.3 million (down 60.14% YoY), and the FY2025 full-year result was $13.2 million, down 49.99% from the prior year.
• Cash & Equivalents eased to $11.3 million in Q2 2026 per OVID's latest filing, from $94.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $168.6 million in Q1 2022 and bottomed at $11.3 million in Q2 2026.
• Historically, Cash & Equivalents has averaged $47.5 million across 5 years, with a median of $30.2 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Cash & Equivalents sank 76.11% in 2022, then jumped 345.04% in 2026.
• Over 5 years, Cash & Equivalents stood at $44.9 million in 2022, then sank by 39.73% to $27.0 million in 2023, then declined by 2.74% to $26.3 million in 2024, then plunged by 49.99% to $13.2 million in 2025, then slipped by 13.88% to $11.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $11.3 million, $94.1 million, and $13.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.